HYLENEX Recombinant (Baxter Healthcare Corporation)
Welcome to the PulseAid listing for the HYLENEX Recombinant drug offered from Baxter Healthcare Corporation. This Endoglycosidase [EPC],Glycoside Hydrolases [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
| LABELER NAME / MANUFACTURER: | Baxter Healthcare Corporation |
| NON-PROPRIETARY NAME: | Hyaluronidase Recombinant Human |
| SUBSTANCE NAME: | HYALURONIDASE RECOMBINANT HUMAN |
| TYPE: | HUMAN PRESCRIPTION DRUG |
| PHARMA CLASS: | Endoglycosidase [EPC],Glycoside Hydrolases [Chemical/Ingredient] |
| ROUTE: | SUBCUTANEOUS |
| DOSAGE FORM: | INJECTION, SOLUTION |
| MARKETING CATEGORY NAME: | NDA |
| START MARKETING DATE: | 2005-12-02 |
| END MARKETING DATE: | 0000-00-00 |
HYLENEX Recombinant HUMAN PRESCRIPTION DRUG Details:
| Item Description | HYLENEX Recombinant from Baxter Healthcare Corporation |
| LABELER NAME: | Baxter Healthcare Corporation |
| DEA SCHEDULE: |
|
| ACTIVE STRENGTH: | 150([USP’U]/mL) |
| START MARKETING DATE: | 2005-12-02 |
| END MARKETING DATE: | 0000-00-00 |
| PRODUCT ID: | 60977-319_07eb92e1-3c44-4567-bbec-a24ed0b39c8a |
| PRODUCT NDC: | 60977-319 |
| APPLICATION NUMBER: | NDA021859 |
Other HYALURONIDASE RECOMBINANT HUMAN Pharmaceutical Manufacturers / Labelers:
